What makes cancer patients resistant to immuno-oncology drugs? Protein signals offer a clue

Checkpoint inhibitors like Merck’s blockbuster PD-1 blocker Keytruda are now widely used to treat several tumor types, but many patients don’t respond to these drugs for reasons that remain a mystery. Now, a team led by researchers at the University of Pittsburgh School of Medicine is shedding new light on a possible mechanism of resistance to PD-1 blockade.

error: Content is protected !!